The ImmunoPeCa study

The ImmunoPeCa study (PIs: Flatmark, Dueland) exploits the MOC31PE immunotoxin as targeted therapy for EpCAM positive peritoneal carcinomatosis from CRC (PC-CRC). MOC31PE binds to the EpCAM surface protein, which is highly expressed by epithelial tumour cells, and has shown rapid cytotoxicity, a distinct mechanism of action, and selectivity via the tumour-associated adhesion molecule EpCAM [Flatmark et al., 2013]. The trial started accrual in August of 2014 and was conducted at OUS NRH as national provider for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for PC-CRC. MOC31PE was administered following the established therapeutic procedures. Pharmacokinetics analysis and treatment outcome will be evaluated in a phase 1 and 2 of the study design.
immunopeca illustrasjon 2


Flatmark, K., Guldvik, I.J., Svensson, H., Fleten, K.G., Flørenes, V.A., Reed, W., Giercksky, K.E., Fodstad, Ø. and Andersson, Y. (2013). Immunotoxin targetting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies. International Journal of Cancer, Vol. 133(6), pp. 1497-1506. (Link)

Frøysnes, I.S., Larsen S.G., Spasojevic, M., Dueland, S., and Flatmark, K. (2016). Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: factors and oncologic outcome in a national patient cohort. Journal of Surgical Oncology, Vol. 114(2), pp. 222-227. (Link)

Frøysnes, I.S., Andersson, Y., Larsen, S.G., Davidson, B., Øien, J.T., Olsen, K.H., Giercksky, K.E., Julsrud, L., Fødstad, Ø., Dueland, S., and Flatmark, K. (2017). Novel treatment with intraperitoneal MOC31PE Immunotoxin in colorectal peritoneal metastasis: Results from the ImmunoPeCa Phase 1 trial. Annals of Surgical Oncology, Vol. 24(7), pp. 1916-1922. (Link)

Leave a Reply